Remed

302550 · KOSDAQ · Health Care · SMALL CAP

Net income turned to a loss.

Remed reported consolidated results for FY2025: revenue of US$17M (−4.1% year on year), operating profit of US$504K (−35.3% year on year) and a net loss of US$122K (from a profit a year earlier).

Earnings(Change of 30% or more in revenue or profit/loss structure (15% for large companies))· FILED 2026-02-25· RCEPT 20260225902000

US$17MRevenue
−4.1%Revenue vs a year earlier
US$504KOperating profit

Converted at 1 USD ≈ ₩1,439.99 (filing-date rate, 2026-02-25 close)

What happened

Remed reported consolidated results for FY2025: revenue of US$17M (−4.1% year on year), operating profit of US$504K (−35.3% year on year) and a net loss of US$122K (from a profit a year earlier).

Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.

RevenueUS$17M
Revenue vs a year earlier−4.1%
Operating profitUS$504K
Net income−US$122K
PeriodFY2025 (consolidated)
Filed2026-02-25, Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SourceDART rcept 20260225902000 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-02-25 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.